• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

BACKGROUND: The American Heart Association (AHA), in conjunction with the National
Institutes of Health, annually reports the most up-to-date statistics related to heart disease …

Background One of the major determinants of exercise intolerance and limiting symptoms
among patients with obstructive hypertrophic cardiomyopathy (HCM) is an elevated …

Abstract Aim The “2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the
Management of Hypertrophic Cardiomyopathy” provides recommendations to guide …

4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

Background: The American Heart Association, in conjunction with the National Institutes of
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …

Background: The American Heart Association, in conjunction with the National Institutes of
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …

Dominant missense pathogenic variants in cardiac myosin heavy chain cause hypertrophic
cardiomyopathy (HCM), a currently incurable disorder that increases risk for stroke, heart …

Hypertrophic cardiomyopathy (HCM) is a relatively common often inherited global heart
disease, with complex phenotypic and genetic expression and natural history, affecting both …

The most common form of genetic heart disease is hypertrophic cardiomyopathy (HCM),
which is caused by variants in cardiac sarcomeric genes and leads to abnormal heart …